Insights into the interplay between KIR gene frequencies and chronic HBV infection in Burkina Faso

Abstract

Background/ObjectiveHepatitis B virus (HBV) infection is the leading risk factor for cirrhosis and hepatocellular carcinoma (HCC). The objective of this investigation was to assess the association between “Killer Cell Immunoglobulin-Like Receptor” (KIR) gene frequencies and chronic HBV infection.MethodsChronic HBV carriers and healthy patients were selected for this study. The viral load for HBV were performed, and SSP-PCR was used to characterize the frequencies of KIR genes.ResultsThe study suggested that inhibitory genes KIR2DL2 (crude OR = 2.82; p < 0.001), KIR2DL3 (crude OR = 2.49; p < 0.001) and activator gene KIR2DS2 (crude OR = 3.95; p< 0.001) might be associated with chronic stages of HBV infection. Conversely the inhibitory genes KIR3DL1 (crude OR = 0.49; p = 0.0018) and KIR3DL2 (crude OR = 0.41; p = 0.005), the activator gene KIR2DS1 (crude OR = 0.48; p = 0.014) and the pseudo gene KIR2DP1 (crude OR = 0.49; p = 0.008) could be associated with immunity against HBV infection. Chronic HBV patients who are carriers for the KIR3DL3 gene (crude OR = 8; p = 0.048) were positive for HBeAg and patients who carried the KIR3DL2 gene (crude OR = 3.21; p = 0.012) had a high HBV viral load compared to the rest of the study population.ConclusionOur data showed evidence of a correlation between the risk of developing chronic HBV infection and certain KIR gene frequencies and also show that KIR3DL1, KIR3DL2, KIR2DS1 might confer a protective status against chronic HBV infection.

KIR2DL5B and HLA DRB1*12 alleles seems to be associated with protection against HIV‐1 in serodiscordant couples in Burkina Faso

“…Previous studies carried out in Burkina Faso have shown the involvement of certain human genetic factors in genetic resistance to HIV‐1 in serodiscordant couples. Kagone et al 3 found a protective role of a variant of the DC‐SIGN promoter and of genetic resistance to HIV‐1 in serodiscordant couples in Burkina Faso; Compaoré et al (2016) 27 found that certain variants of APOBEC3G would protect against HIV‐1 infection 4,28,29 . Sorgho et al (2018−2019) showed that certain variants of KIR genes were associated with protection against HBV and HIV‐1 infection 4,29 and Zoure et al 30 found that HLA‐DRB1*11 allele deletion was associate with obesity/overweight, which is a risk for cancer development 30 in the same country.…”

“…Kagone et al 3 found a protective role of a variant of the DC-SIGN promoter and of genetic resistance to HIV-1 in serodiscordant couples in Burkina Faso; Compaoré et al (2016) 27 found that certain variants of APOBEC3G would protect against HIV-1 infection. 4,28,29 protection against HBV and HIV-1 infection 4,29 and Zoure et al 30 found that HLA-DRB1*11 allele deletion was associate with obesity/overweight, which is a risk for cancer development 30 in the same country.…”

“…Sorgho et al (2018Sorgho et al ( −2019 showed that certain variants of KIR genes were associated withT A B L E 1 T A B L E 2 Frequencies of intercourse and antiretroviral treatment in serodiscordant couples. Variables HIV+ n = 19 HIV− n = 19 Total n = 38 Abbreviation: HIV, human immunodeficiency virus.T A B L E 3 Frequencies of KIR genes in serodiscordant couples.…”

Association of KIR haplotypes with propensity for developing chronic hepatitis B induced liver diseases (cirrhosis and hepatocellular carcinoma) and HIV-1 infection in a West African Cohort

“…Serological markers for HIV-1 and HCV of HBV infected patients were detected and serological markers for HBV and HCV of HIV-1 infected patients were detected using HIV Human Immunodefi ciency Virus Rapid Test Device (Abon Biopharm Guangzhou, Co., Ltd Chine), HBV One Step Hepatitis B Virus Combo Test Kits (Abon Biopharm Guangzhou, Co., Ltd. China) and HCV Hepatitis C Virus Rapid Test Device (Abon Biopharm Guangzhou, Co., Ltd Chine), respectively to rule out possible cases of infection with these viruses. This was previously described by Sorgho, et al [6,7]. Samples collection, measurement of HBV, HCV and HIV viral markers as well as and quantifi cation of lymphocytes TCD4, HIV-1 and HBV viral load quantifi cation, DNA extraction and KIR genotyping were also previously described by the same authors [6,7].…”

“…This was previously described by Sorgho, et al [6,7]. Samples collection, measurement of HBV, HCV and HIV viral markers as well as and quantifi cation of lymphocytes TCD4, HIV-1 and HBV viral load quantifi cation, DNA extraction and KIR genotyping were also previously described by the same authors [6,7].…”